Simbec-Orion, a mid-sized Contract Research Organization (CRO), and biotx.ai, a company specializing in AI-powered causal modeling for drug development, have officially revealed their strategic partnership to integrate AI-driven insights and predictive models into their clinical trial design support.

Simbec-Orion, with a wealth of experience in the fields of oncology, rare diseases, and clinical pharmacology studies, offers over four decades of expertise in aiding biotech and small to mid-sized pharmaceutical companies in intricate early-stage clinical development, particularly within specialized patient populations.

Simbec-Orion, expressed his enthusiasm for the partnership, stating, "We are excited to announce our strategic collaboration with biotx.ai. The data-driven predictions provided by biotx.ai will furnish our clients with a cost-effective means to accumulate additional data to underpin their clinical development strategy. This will be achieved by harnessing causal AI models to forecast clinical trial outcomes and utilizing these insights to inform our clinical trial design."

Biotx.ai's causal AI technology proficiently replicates the outcomes of clinical trials through their extensive human genetic database, encompassing 3.3 million cases spanning over 12,000 diseases, each accompanied by a comprehensive phenotype analysis. The efficacy of their causal AI has been proven through the successful prediction of the outcomes of eight distinct COVID-19 trials and has been employed across a spectrum of therapeutic areas.

Biotx.ai, emphasized the potential of causal models within the realm of clinical drug development, remarking, "Causal models at scale empower drug development: They enable us to pinpoint all the mechanisms and diseases causally influenced by a given drug. We identify the most suitable indication for our clients' drug, supply evidence regarding the absence of specific side effects when compared to rival compounds, and, most notably, provide substantiation for the effectiveness of their compounds in humans. For several of our clients, this has played a pivotal role in securing funding for their phase 2 trials."

Regarding the value of utilizing AI-powered causal models to secure funding, Fabrice Chartier added, "In the fiercely competitive biotech arena, investors are increasingly insistent on obtaining more data and are becoming more discerning in their project selections. We offer support to our clients during these crucial early development stages, leveraging our knowledge and experience to shape their clinical development and corporate strategy. Providing our clients with the opportunity to accumulate data on projected clinical trial outcomes before venturing into clinical trials serves as a valuable tool for showcasing a drug's true potential to investors. With this technology, we can also provide guidance on endpoints and protocol design to optimize the chances of conducting a successful study."

 

Source: prnewswire.com

Report Abuse